A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00528827 |
Recruitment Status :
Withdrawn
(Due to the sale of Cardene IV, the sponsor has stopped enrollment and withdrawn the study. No safety issues were identified.)
First Posted : September 12, 2007
Last Update Posted : March 16, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension | Drug: Cardene® I.V. | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension |
Study Start Date : | September 2007 |
Actual Primary Completion Date : | December 2008 |
Actual Study Completion Date : | December 2008 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: 1 |
Drug: Cardene® I.V.
|
Experimental: 2
5 mcg
|
Drug: Cardene® I.V.
|
Experimental: 3
2.5
|
Drug: Cardene® I.V.
|
Experimental: 4
0.5
|
Drug: Cardene® I.V.
|
- Mean percent change in SBP (Systolic Blood Pressure) from baseline during the 30-minute Randomized, Placebo-controlled Infusion Phase for each dose level of Cardene I.V. compared to placebo. [ Time Frame: 30 minutes ]
- 1) Mean percent change in SBP and DBP between various phases of dosing. 2) Proportion of subjects requiring additional antihypertensive medications during the treatment period. 3) Mean effective dose of Cardene I.V. [ Time Frame: 72 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years to 16 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Evidence of Stage 1 or Stage 2 systolic hypertension at the time of screening.
- Male or female subjects, ages ≥2 to ≤16 years.
-
Females who meet either of the following criteria:
-
Non-childbearing potential , as documented by:
- a medical history of non-menstruation or
- surgical sterility from oophorectomy and/or hysterectomy. * A history of tubal ligation or evidence of a sterile sexual partner is insufficient evidence of non-childbearing potential.
- Childbearing potential: provide a negative urine pregnancy test within 24 hours of administration of study drug and agree to utilize effective contraception or remain abstinent during the entire treatment and follow-up periods of the study.
-
- Signed informed consent provided by an authorized subject representative and assent from subject, if feasible (based on local Institutional Review Board (IRB)/ethics panel requirements).
Exclusion Criteria:
- Subjects with seizures, altered state of consciousness, chest pain, facial palsy or intracranial hemorrhage at the time of screening.
- Receiving antihypertensive medication within a duration specified prior to screening.
- Treatment with cimetidine within 10 hours prior to dosing with study drug.
- Any known or suspected allergy to nicardipine hydrochloride.
- A calculated Glomerular Filtration Rate (GFR) under 30 mL/min/ 1.73 m2 as calculated using the Schwartz formula and the associated K values.
- Known history of severe aortic stenosis.
- Known history of severe left ventricular dysfunction.
- Known history of severely impaired hepatic function with portal hypertension.
- Liver function test (AST or ALT) results greater than or equal to twice the upper limit of normal.
- Receiving maintenance hemodialysis at screening or anticipated to require hemodialysis within 12 hours following initiation of treatment with study drug.
- Receiving a blood transfusion at screening or anticipated to require blood transfusions within 12 hours following initiation of treatment with study drug.
- Lack of appropriate intravenous (I.V.) access.
- Inability to tolerate a large-volume I.V. infusion.
- Any other condition or prior therapy, which, in the opinion of the investigator, would make the subject unsuitable for this study.
- Participation in any phase of another clinical research study involving the evaluation of another investigational drug or device within 30 days before randomization.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00528827
United States, California | |
Beverly Hills, California, United States, 90211 | |
United States, Florida | |
Miami, Florida, United States, 33145 |
Responsible Party: | Facet Biotech |
ClinicalTrials.gov Identifier: | NCT00528827 |
Other Study ID Numbers: |
Cardene® I.V. 1406 |
First Posted: | September 12, 2007 Key Record Dates |
Last Update Posted: | March 16, 2012 |
Last Verified: | March 2012 |
Hypertension, High Blood Pressure, Pediatric Hypertension, High blood pressure in children |
Hypertension Vascular Diseases Cardiovascular Diseases Nicardipine Antihypertensive Agents Calcium Channel Blockers |
Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Vasodilator Agents |